Bacterial colicin-immunity protein protein purification system
US-2024417426-A1 · Dec 19, 2024 · US
Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli
US10035826B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10035826-B2 |
| Application number | US-201615150204-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 9, 2016 |
| Priority date | Feb 18, 2005 |
| Publication date | Jul 31, 2018 |
| Grant date | Jul 31, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunizing against MNEC infections.
First claim
Opening claim text (preview).
What is claimed: 1. An immunogenic composition comprising: (1) an immunologically effective amount of polypeptide comprising: (a) the amino acid sequence consisting of SEQ ID NO: 810, (b) an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 810; or (c) an amino acid sequence having at least 95% sequence identity to an amino acid sequence of (a) and including a fragment of at least 10 consecutive amino acids from an amino acid sequence of (a) and (2) an immunologically effective amount of adjuvant, wherein the immunologically effective amount of polypeptide is at least 1 μg/ml. 2. The immunogenic composition of claim 1 , wherein said fragment comprises at least one B-cell epitope of (a). 3. The immunogenic composition of claim 1 , further comprising a pharmaceutically acceptable carrier. 4. The immunogenic composition of claim 1 , wherein the composition is sterile.
Assignees
Inventors
Classifications
Immunostimulants · CPC title
Antibacterial agents · CPC title
- C07K14/245Primary
Escherichia (G) · CPC title
expressing foreign proteins · CPC title
comprising antibodies · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10035826B2 cover?
- Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunizing against MNEC infections.
- Who is the assignee on this patent?
- Glaxosmithkline Biologicals Sa, J Craig Venter Inst Inc, J Craig Venture Inst Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K14/245. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 31 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).